1. Home
  2. CLPS vs FGEN Comparison

CLPS vs FGEN Comparison

Compare CLPS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

HOLD

Current Price

$0.85

Market Cap

25.8M

Sector

Technology

ML Signal

HOLD

Logo FibroGen Inc

FGEN

FibroGen Inc

HOLD

Current Price

$9.51

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
FGEN
Founded
2005
1993
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
35.6M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
CLPS
FGEN
Price
$0.85
$9.51
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$146.50
AVG Volume (30 Days)
17.2K
26.2K
Earning Date
10-17-2025
11-10-2025
Dividend Yield
14.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
53.38
Revenue
$164,481,414.00
$8,298,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.16
Revenue Growth
15.17
N/A
52 Week Low
$0.82
$4.85
52 Week High
$1.88
$21.94

Technical Indicators

Market Signals
Indicator
CLPS
FGEN
Relative Strength Index (RSI) 43.24 54.76
Support Level $0.86 $8.37
Resistance Level $0.95 $9.09
Average True Range (ATR) 0.03 0.54
MACD -0.00 0.22
Stochastic Oscillator 3.50 61.29

Price Performance

Historical Comparison
CLPS
FGEN

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Share on Social Networks: